Wayland Group Corp Stock Canadian Securities Exchange
Equities
CA5667241007
Pharmaceuticals
Sales 2016 | 4.06 5.54 | Sales 2017 | 3.22 4.4 | Capitalization | 203M 277M |
---|---|---|---|---|---|
Net income 2016 | -8M -10.91M | Net income 2017 | -67M -91.38M | EV / Sales 2016 * | - |
Net Debt 2016 | 9.13 12.45 | Net cash position 2017 | 0.42 0.57 | EV / Sales 2017 | 63,046,727 x |
P/E ratio 2016 * |
-
| P/E ratio 2017 |
-2.13
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
1st Jan change | Capi. | |
---|---|---|
+37.37% | 6.02B | |
-15.69% | 4.49B | |
-12.46% | 3.06B | |
-0.12% | 3.04B | |
+0.47% | 2.61B | |
+36.06% | 1.81B | |
+0.84% | 1.66B | |
-10.60% | 1.63B | |
-12.03% | 1.55B |